ES2192199T3 - Ligandos de la familia eph biologicamente activos. - Google Patents

Ligandos de la familia eph biologicamente activos.

Info

Publication number
ES2192199T3
ES2192199T3 ES95916204T ES95916204T ES2192199T3 ES 2192199 T3 ES2192199 T3 ES 2192199T3 ES 95916204 T ES95916204 T ES 95916204T ES 95916204 T ES95916204 T ES 95916204T ES 2192199 T3 ES2192199 T3 ES 2192199T3
Authority
ES
Spain
Prior art keywords
biologically active
ligandos
eph
active family
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916204T
Other languages
English (en)
Other versions
ES2192199T5 (es
Inventor
Samuel Davis
Nicholas Gale
Thomas H Aldrich
Peter C Maisonpierre
Mitchell Goldfarb
George D Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27499262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2192199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/299,567 external-priority patent/US5747033A/en
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of ES2192199T3 publication Critical patent/ES2192199T3/es
Application granted granted Critical
Publication of ES2192199T5 publication Critical patent/ES2192199T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE IDENTIFICAN NUEVOS LIGANDOS QUE SE UNEN A LA FAMILIA DE RECEPTORES EPH, Y SE DESCRIBEN METODOS PARA OBTENER LOS LIGANDOS SOLUBLES EN FORMA BIOLOGICAMENTE ACTIVA. LOS CLONES DE C-DNA QUE CODIFICAN PARA ESTAS NUEVAS PROTEINAS PERMITEN LA PRODUCCION DE LAS PROTEINAS RECOMBINANTES, QUE SON UTILES PARA SUSTENTAR CELULAS NEURONALES Y OTRAS POBLACIONES CELULARES QUE PORTAN RECEPTORES.
ES95916204T 1994-04-04 1995-04-04 Ligandos de la familia eph biologicamente activos. Expired - Lifetime ES2192199T5 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US22207594A 1994-04-04 1994-04-04
US222075 1994-04-04
US22940294A 1994-04-12 1994-04-12
US229402 1994-04-12
US08/299,567 US5747033A (en) 1993-10-28 1994-09-01 Method of enhancing the biological activity of Eph family ligands
US299567 1994-09-01
US32742394A 1994-10-21 1994-10-21
US327423 1994-10-21

Publications (2)

Publication Number Publication Date
ES2192199T3 true ES2192199T3 (es) 2003-10-01
ES2192199T5 ES2192199T5 (es) 2007-07-01

Family

ID=27499262

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95916204T Expired - Lifetime ES2192199T5 (es) 1994-04-04 1995-04-04 Ligandos de la familia eph biologicamente activos.

Country Status (9)

Country Link
EP (1) EP0758381B2 (es)
JP (1) JP3686084B2 (es)
AT (1) ATE232901T1 (es)
AU (1) AU691915B2 (es)
CA (1) CA2187167A1 (es)
DE (1) DE69529674T3 (es)
ES (1) ES2192199T5 (es)
IL (1) IL113252A0 (es)
WO (1) WO1995027060A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
WO1996013518A1 (en) * 1994-10-27 1996-05-09 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
WO1997014966A1 (en) * 1995-10-13 1997-04-24 Mount Sinai Hospital Corporation Method of activating a novel ligand regulatory pathway
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6696557B1 (en) 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
CA2259157A1 (en) * 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
US5994112A (en) * 1996-10-09 1999-11-30 Incyte Pharmaceuticals, Inc. Human protein tyrosine kinase
CA2355163A1 (en) * 1998-12-18 2000-06-29 Mount Sinai Hospital Three dimensional structure of a sterile alpha motif domain
US7008781B1 (en) 1998-12-23 2006-03-07 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
FI952328L (fi) * 1992-11-13 1995-07-10 Amgen Inc eck-respetorin lignandeja
CA2148484A1 (en) * 1992-11-13 1994-05-26 Stewart Lyman Novel cytokine designated elk ligand
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek

Also Published As

Publication number Publication date
EP0758381B2 (en) 2006-11-15
EP0758381B1 (en) 2003-02-19
DE69529674D1 (de) 2003-03-27
WO1995027060A2 (en) 1995-10-12
ES2192199T5 (es) 2007-07-01
JP3686084B2 (ja) 2005-08-24
AU2278995A (en) 1995-10-23
AU691915B2 (en) 1998-05-28
CA2187167A1 (en) 1995-10-12
IL113252A0 (en) 1995-07-31
JPH09511401A (ja) 1997-11-18
DE69529674T2 (de) 2003-12-18
ATE232901T1 (de) 2003-03-15
WO1995027060A3 (en) 1995-11-02
EP0758381A1 (en) 1997-02-19
DE69529674T3 (de) 2007-06-28

Similar Documents

Publication Publication Date Title
ES2192199T3 (es) Ligandos de la familia eph biologicamente activos.
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
IL100343A0 (en) G protein coupled glutamate receptors
DE69738586D1 (de) Hohe expressionsrate von proteinen
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
NO965362L (no) Syntetiske lederpeptidsekvenser
DE3851153D1 (de) Genetische modifizierung von endothelialen zellen.
DE68929402D1 (de) Verfahren zur herstellung von wasserlöslichen polypeptiden
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
ES8103976A1 (es) Un metodo de producir proteinas de interferon humano de for-ma le
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
SG65593A1 (en) Totally synthetic affinity reagents
ATE233788T1 (de) Interleukin-15-rezeptoren
PL349158A1 (en) Method of enhancing the biological activity of ligands
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
DE69712124D1 (de) Hormones de croissance humaines mutantes et leur utilisation
ATE314470T1 (de) Biologisch aktive liganden der eph familie
DE59814002D1 (de) Sekretion von tragergebundenen proteinen in das periplasma und in den extrazellulären raum
IL127363A0 (en) IL-1/TNF-alpha-activated kinase and methods of making and using the same
DE59911530D1 (de) Zellpermeabilität-vermittelndes polypeptid
MXPA02011938A (es) Adn que codifica para un receptor de histamina de mamifero del subtipo h4.
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
CA2236001A1 (en) Biologically active eph family ligands
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.